Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Aritinercept · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Aritinercept | EXPERIMENTAL | Double-Blind Treatment Period: Aritinercept by subcutaneous injection Open-Label Treatment Period: Aritinercept by subcutaneous injection |
| Placebo | PLACEBO_COMPARATOR | Double-Blind Treatment Period: Placebo by subcutaneous injection Open-Label Treatment Period: Aritinercept by subcutaneous injection |
| Name | Type | Description |
|---|---|---|
| Aritinercept | DRUG | For subcutaneous injection |
| Placebo | OTHER | For subcutaneous injection |
Key Inclusion Criteria: * Adult patients (18-85 years old) * Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG * Additional inclusion criteria are defined in the protocol Key Exclusion Criteria: * Current or medical history of malignancy within the last 5 years * Pregnant, breastfeed...